Hypothesis

Hypertrophic adipocytes release extracellular vesicles (EVs) that carry enzymatically active lysyl oxidase (LOX) bound to nascent collagen fragments and a specific miRNA signature (miR‑29b‑3p, miR‑21‑5p, miR‑155) that together reprogram resident macrophages in distal adipose depots toward a pro‑fibrotic phenotype, accelerating inter‑depot ECM stiffening.

Mechanistic Rationale

• EV cargo reflects adipocyte stress: In hypertrophic visceral adipocytes, chronic inflammation and hypoxia upregulate LOX transcription and increase collagen synthesis. LOX is secreted as a pro‑enzyme that requires extracellular copper‑dependent activation; we propose that a fraction of nascent collagen‑LOX complexes is captured within budding EVs, preserving enzymatic activity within the vesicle lumen.
• miRNA payload modulates macrophage phenotype: Visceral adipocyte EVs are enriched in miR‑29b‑3p (suppresses collagen‑degrading MMPs), miR‑21‑5p (promotes TGF‑β signaling) and miR‑155 (drives M1 polarization). Transfer of these miRNAs to subcutaneous adipose macrophages suppresses MMP‑9/13 expression, enhances TIMP‑1 secretion, and sustains a pro‑inflammatory, pro‑fibrotic state.
• Depot‑specific amplification: Subcutaneous adipocytes normally exhibit higher hyperplasia capacity and lower basal LOX activity. Upon uptake of visceral‑derived EVs, their fibroblasts and pre‑adipocytes experience a sudden increase in collagen crosslinking and reduced matrix degradation, tipping the balance toward fibrosis despite lower intrinsic hypertrophic signaling.
• Feedback loop amplifies inter‑depot spread: Fibrotic subcutaneous adipocytes, in turn, release their own EVs bearing similar LOX‑collagen complexes and miRNA motifs, creating a bidirectional wave that propagates stiffness throughout the adipose organ.

Testable Predictions

1. Isolation and activity assay: EVs isolated from visceral adipose tissue of obese mice will show higher LOX enzymatic activity (measured via Amplex Red‑based collagen crosslinking assay) than EVs from subcutaneous tissue; inhibition of LOX with β‑aminopropionitrile will abolish this activity.
2. miRNA signature profiling: Small‑RNA sequencing of EV fractions will reveal a consistent enrichment of miR‑29b‑3p, miR‑21‑5p, and miR‑155 in visceral‑derived EVs compared with subcutaneous EVs (p < 0.01, DESeq2).
3. Functional transfer in vitro: Culturing subcutaneous adipose‑derived macrophages with visceral adipocyte EVs will decrease MMP‑9 mRNA (−40 % ± 5) and increase TIMP‑1 mRNA (+35 % ± 4) relative to macrophage‑only controls; transfection with anti‑miR‑29b‑3p will rescue MMP‑9 expression.
4. In vivo blockade: Treating obese mice with GW4869 (neutral sphingomyelinase inhibitor) to suppress EV release will reduce LOX activity in subcutaneous fat by ~30 % and lower collagen crosslink density (hydroxyproline assay) without affecting adipocyte size, concomitant with improved insulin tolerance (ITT AUC ↓ 25 %).
5. Depot‑specific gene expression: RNA‑seq of subcutaneous adipose stromal vesicles from GW4869‑treated mice will show normalization of fibrotic genes (Col1a1, Acta2, Tgfb1) to levels seen in lean controls, while visceral depot remains unchanged, confirming directional spread.

Potential Challenges and Controls

• Verify that observed LOX activity is vesicle‑associated and not due to soluble LOX contamination (include ultracentrifugation and protease protection controls).
• Ensure EV uptake is mediated by specific receptors (e.g., integrins αvβ3/α5β1) using blocking antibodies to rule out nonspecific endocytosis.
• Account for compensatory changes in adipocyte hypertrophy; measure adipocyte volume distribution via histology to confirm that fibrosis changes are independent of cell size alterations.

This hypothesis extends the existing framework by positioning adipocyte‑derived EVs as a mechanistic conduit that translates local hypertrophic stress into a systemic fibrotic signal, offering a testable target for inter‑depot intervention.